Seaside Therapeutics Initiates Phase 2b Study Of STX209 In Autism Spectrum Disorders

Friday, Aug. 5th 2011 6:40 AM

Seaside Therapeutics, Inc. announced today the initiation of a randomized, double-blind, placebo-controlled Phase 2b study to evaluate the effects of STX209 (arbaclofen) on social impairment in children, adolescents and adults (ages 5 to 21) with autism spectrum disorders (ASD). The Company announced positive results from an open-label Phase 2a study of STX209 in September of 2010.

Posted on Friday, Aug. 5th 2011 6:40 AM | by Share of Cost | in Share of Cost | Comments Off on Seaside Therapeutics Initiates Phase 2b Study Of STX209 In Autism Spectrum Disorders